Active Ingredient History
Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these is not yet established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. It is FDA approved for the treatment of asthma, prevention of exercise-induced bronchospasm, maintenance treatment of chronic obstructive pulmonary disease. Common adverse reactions include musculoskeletal pain, headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, throat irritation, viral respiratory infection. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents. Coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Injuries (Phase 3)
Adipose Tissue (Phase 2)
Asthma ()
Asthma, Exercise-Induced (Phase 3)
Body Contouring (Phase 2)
Body Weight (Phase 2)
Bronchial Spasm (Phase 4)
Bronchiolitis Obliterans (Phase 3)
Bronchitis, Chronic (Phase 4)
Candidiasis, Oral (Phase 4)
Depression (Phase 4)
Emphysema (Phase 4)
Exercise (Phase 4)
Healthy Volunteers (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 3)
Lung Diseases (Phase 3)
Lung Diseases, Obstructive (Phase 2)
Quality of Life (Phase 4)
Rhinitis, Allergic (Phase 4)
Spinal Cord Injuries (Phase 1)
Therapeutic Equivalency (Phase 1)
Thyroid Gland (Phase 2)
Voice Disorders (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
